The effects of the gut microbiota on whole-body processes
The human body is made up of approximately 37 trillion human cells, arranged by their type into tissue and organ systems that facilitate all functions of human life (Bianconi et al., 2013) . It has been calculated that the dynamic population of bacterial cells living on and within the human body, termed the human microbiota, is at least equal in number to the human cells (Luckey, 1972; Sender et al., 2016) . Most of these microbes (greater than 70%) reside within the gastrointestinal tract (Sekirov et al., 2010; Tlaskalova-Hogenova et al., 2011) , with more than 1000 different bacterial species regularly colonizing the human gut (Qin et al., 2010; Sekirov et al., 2010) . Considering that a range of bacterial metabolites and immune-modulating mediators are able to traverse mucosal barriers and influence human immune cells, it is anticipated that both the normal and pathological microbiota of the human gut impact local and systemic health of the host (Chan et al., 2013; Li et al., 2016; Logan et al., 2016; Tlaskalova-Hogenova et al., 2011) .
Although this link has yet to be fully explored, it has been suggested that high levels of intestinal microbial richness, diversity and stability may help promote overall human health (Coyte et al., 2015; Le Chatelier et al., 2013) . For example, by fermenting otherwise non-digestible compounds, such as starch, the gut microbiota routinely provide their host with nutrients in the form of several short chain fatty acids (SCFAs) including formate, acetate, propionate, and butyrate (Morrison and Preston, 2016; Tojo et al., 2014) . In addition to serving as signaling molecules between microbes, SCFAs are also a source of energy for human cells and tissues (Morrison and Preston, 2016 Butyrate, for example, is the preferred source of energy for colonocytes (Clausen and Mortensen, 1995) . The SCFAs acetate and propionate have been shown to reduce adipocyte lipolysis, regulate appetite, improve leptin secretion by adipocytes, and enhance whole-body glucose homeostasis; thereby SCFAs impact the maintenance of the overall energy balance in humans (Chambers et al., 2015; Hong et al., 2005; Zaibi et al., 2010) . Additionally, SCFAs can act as signaling molecules from bacteria to host cells; they play an important role in maintaining the integrity of intestinal epithelial cell layer by regulating the expression of tight junction proteins (Manco et al., 2010; Morrison and Preston, 2016; Wang et al., 2012; Zhou et al., 2014) . The SCFAs propionate, butyrate, acetate, and valerate have been associated with increased expression of the tight junction proteins zonula occludens (ZO)-1 and claudin-1 by intestinal epithelial cells. This increase in tight junction protein expression can inhibit the translocation of lipopolysaccharide (LPS) into the submucosae, and thereby reduce inappropriate immune cell activation (Manco et al., 2010; Morrison and Preston, 2016; Wang et al., 2012; Zhou et al., 2014) .
When humans consume fruits and vegetables, they ingest thousands of dietary polyphenols. Some of these polyphenols possess significant antioxidant, anti-carcinogenic, anti-inflammatory, anti-microbial, or other biological effects (Valdes et al., 2015) . However, the physiological impact of various beneficial polyphenols depends on their intestinal absorption. Often, it is the metabolic actions of intestinal microbiota that modify the structure of polyphenols, which allows these compounds to cross the intestinal mucosa and enter into the circulation (Ader et al., 1996; Hollman and Katan, 1997; Manach et al., 2004) . For example, many flavonol compounds, such as kaempferol, quercetin, and myricetin are metabolized by Clostridium spp., while anthocyanins, such as cyanidin, peonidin, and malvidin are metabolized by Lactobacillis spp. into compounds that can traverse the intestinal mucosa (Marin et al., 2015) . These polyphenol compounds can then be further modified and transported to other tissues and organs to exhibit their various beneficial effects. For example, the anthocyanin metabolites delphinidin 3-O-glucoside and cyanidin 3-O-glucoside have been shown to be protective against ischemic heart injury ( Skemiene et al., 2015) .
Intestinal microbiota also provide humans with many essential micronutrients, including thiamine, riboflavin, biotin, folate, B vitamins, vitamin A, vitamin D, and vitamin K (Albert et al., 1980; Biesalski, 2016; Stevens and Hume, 1998) . Vitamin K, for example, is essential for the process of thrombosis (Merli and Fink, 2008) . In many developed countries, neonates, who do not yet have an established intestinal microbiome to produce vitamin K for them, are routinely given intramuscular injections of 0.5-1.0 mg of vitamin K 1 shortly after birth. This injection is given in order to prevent hemorrhagic disease of the newborn, which presents as unexpected bleeding typically with gastrointestinal hemorrhage (McMillan, 1997) . The notion that gut microbiota have an important role in promoting overall nutritional health in humans is supported by studies conducted in developing countries. One such study showed that a low level of fecal microbiota diversity correlated with poor health, as on average 37 bacterial genera were found in malnourished children compared to the 62 bacterial genera identified in healthy children (Monira et al., 2011) . In addition to nutritional improvement, Bifidobacteria spp. have been implicated in positively regulating calcium absorption by adolescents, which leads to healthy bone density and strength (Weaver, 2015; Winham et al., 2015) .
Several SCFAs have also been implicated in the training and regulation of the human immune system. For example, acetate, butyrate, and propionate have been shown to protect against mounting an inappropriate immune response to innocuous antigens, such as food particles (Tan et al., 2016) . Other studies have demonstrated that the SCFA propionic acid significantly reduces the expression of the immune cytokines interleukin (IL)-2, IL-4, IL-5, and IL-6 by stimulated T cells, while the SCFA butyric acid nearly eliminates the expression of these cytokines by stimulated T cells (Kim et al., 2014; Kurita-Ochiai et al., 1995) . It has also been shown that the SCFAs positively regulated human plasma B cell maturation, as established by a 1.3-fold increase in cluster of differentiation (CD)20 -/CD38 + B cells following stimulation with either acetate, propionate or butyrate (Kim et al., 2016) . This study further revealed that stimulation with acetate, propionate or butyrate led to 1.8-fold, 2.5-fold and three-fold upregulation in immunoglobulin (Ig)G production by human B cells, respectively, as well as an approximately 4.5-fold upregulation in IgA production by the three SCFAs studied (Kim et al., 2016) . Additionally, a recent clinical report analyzing the relationship between gut microbiota, SCFA metabolites, and markers of inflammation in healthy adults highlighted that a two-week whole-grain-based diet led to increased fecal acetate concentrations in these subjects, compared to the group of adults who consumed refined grains (Vanegas et al., 2017) . The increase in fecal acetate was associated with a higher percentage of circulating memory T cells (Vanegas et al., 2017) . Thus, the digestion of complex carbohydrates into SCFAs by intestinal bacteria may play a significant role in the development of the host immune system and immune cell responses. Furthermore, gut microbiota have been implicated in the regulation of brain health, since oral antibiotic administration in specific pathogen free (SPF) mice resulted in upregulated expression of the critical neuronal survival factor brain-derived neurotrophic factor (BDNF) in the hippocampus, but downregulated expression of BDNF in the amygdala, indicating the relationship between the microbiota and central nervous system (CNS) is complex (Bercik et al., 2011) . Human studies have revealed that decarboxylases secreted by Clostridium sporogenes contribute to the conversion of tryptophan to tryptamine, a well-characterized neuromodulator and neurotransmitter, which is known to evoke the release of serotonin and dopamine by neurons Wolfel and Graefe, 1992) . Furthermore, the gram-positive intestinal bacteria Lactobacillus spp. and Bifidobacteria spp. can metabolize glutamate to produce γ-aminobutyric acid (GABA), which is a major inhibitory neurotransmitter of the CNS (Barrett et al., 2012; Hu et al., 2016) .
Experiments utilizing germ-free (GF) mice indicate that the presence of intestinal microbiota helps maintain the integrity of the bloodbrain barrier (BBB) by positively regulating expression of the tight junction proteins occludin and claudin-5 (Braniste et al., 2014) . The expression of these BBB proteins was reduced by up to 75% in the GF mice, compared to mice with intact microbiota (Braniste et al., 2014) . Moreover, it was demonstrated that microglia, the immune cells of the brain, from GF mice exhibited a more branched morphology and were larger when compared to cells from SPF mice brains . This morphological difference correlated with the whole-brain increases in the expression of ionized calcium-binding adapter molecule (IBA)-1, a marker of microglia activation, in the SPF mice . The GF mice also displayed a significantly diminished response to stimulation with LPS, when compared to SPF mice, as indicated by lowered secretion of IL-1β, IL-6, and monocyte chemoattractant protein (MCP)-1 by microglia harvested from GF mice . These findings indicate that microglia in SPF mice brains may be better prepared to respond to pathological stimuli compared to the microglia in the GF mice.
The human microbiota: role in training the immune system
The most important function of human microbiota is arguably their role in the development and maturation of the immune system. Colonization of the host by microbiota begins in utero, and the wholebody microbial colonization increases significantly the instant an infant is born. Bacteria continue to colonize their host until a stable, yet somewhat dynamic, commensal microbial community has developed (usually around the age of three years) (Collado et al., 2016; Koenig et al., 2011; Li et al., 2016; Palmer et al., 2007) . The human microbiota train the immune system to tolerate a vast array of commensal antigens, instruct intestinal epithelial cells and underlying immune cells to respond appropriately to microbial signals, while establishing immune homeostasis and fending off dysregulated inflammation (Arrieta and Finlay, 2012) . In fact, insufficient exposure to pathogenic agents, as well as symbiotic microorganisms, such as the gut microbiota, has been shown to dramatically increase the incidence of autoimmune and allergic diseases, particularly in children; a phenomenon, which has been termed "the hygiene hypothesis" for this group of human pathologies (Okada et al., 2010) . This hypothesis is supported by prominent global epidemiological data (Kondrashova et al., 2005; Okada et al., 2010) . For example, the incidence of type 1 diabetes mellitus (T1DM), an autoimmune disease characterized by destruction of pancreatic β-cells and subsequent inability to regulate blood glucose levels, is six-fold higher in Finland (a more developed country), than it is in the geographically adjacent Karelian republic of Russia (a less developed territory) (Kondrashova et al., 2005) . This finding is particularly unusual, as the genetic background of individuals from these adjacent territories is very similar (Kondrashova et al., 2005) . The proposed reason for this dramatic difference in T1DM prevalence is early exposure to a wider diversity of microbial antigens in the less developed territory (Munyaka et al., 2014) . Exposure of humans to various endotoxins during their first year of life, as well as exposure to hookworms, may protect against the development of asthma, a disease that is more prevalent in urbanized areas (Okada et al., 2010) . Therefore, early interactions with a wide variety of innocuous microorganisms, and a stable and healthy gut microbiota, are essential for one's overall health.
The human microbiota: microbial dysbiosis
Microbial dysbiosis has been broadly defined as a shift in the composition of the bacteria that comprise the human microbiota, from a typically diverse and commensal microbial community towards a more maladaptive and pathogenic profile (Keightley et al., 2015; Patterson et al., 2014) . When microbial dysbiosis arises, detrimental effects, including chronic illness, are more likely to occur (Patterson et al., 2014) . This shift of normal gut microbiota to a more pathogenic or detrimental profile can lead to increased intestinal permeability, which can trigger inappropriate immune response (Leclercq et al., 2014) . For example, even a small rise in circulating LPS levels (1 ng/kg increase) has shown to elevate serum concentrations of IL-6 and TNF-α 300 and 200 fold, respectively (Herlitz et al., 2015) . Microbial dysbiosis has been implicated as a contributing factor in a number of disorders and diseases, including T1DM and type 2 diabetes mellitus (T2DM), cardiovascular disease, liver disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), multiple sclerosis, autism, Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) (Fang, 2016; Hill et al., 2014; Li et al., 2016) . Even though each of these diseases has its own unique defining characteristics, all of them are characterized, at least in part, by chronic inflammation, which may be the result of the associated microbial dysbiosis.
The microbial dysbiosis observed in IBD can present in many different forms, but several studies have described this disease as being characterized by an increase in Actinobacteria and Proteobacteria phyla and Ruminococcus gnavus, as well as a decrease in Bacteroidetes phylum, and Lachnospiraceae family, Dialister invisus, Faecalibacterium prausnitzii, Clostridium leptum, Bifidobacterium adolescentis, when compared to healthy controls, thereby implicating these particular bacteria as being important in maintaining gastrointestinal health (Frank et al., 2007; Joossens et al., 2011; Manichanh et al., 2006) . This altered microbial signature, as well as the presence of other pathogenic bacteria, may be partially responsible for the hallmark intermittent immune attacks in the colon and small intestines associated with IBD, in which the body's immune system attacks its own cells, resulting in urgent bowel movements, diarrhea, bloody stool, abdominal pain, and cramping (Assadsangabi and Lobo, 2013) .
Individuals with T2DM, a metabolic disease characterized by insulin resistance and poor glucose regulation, display a significantly increased proportion of Bacteriodetes phylum, and a significantly diminished abundance of Firmiculetes phylum, as well as a decrease in Clostridia spp. present in the gut when compared to healthy controls (Larsen et al., 2010) . Enhanced colonization by various opportunistic pathogenic bacteria including Clostridium symbiosum, Eggerthella lenta, and Escherichia coli has also been observed in the guts of T2DM patients, compared to healthy individuals (Qin et al., 2012) . Functional analysis revealed that the intestinal microbiota of individuals with T2DM had enhanced oxidative stress resistance, enriched methane metabolism, and improved sulphate reduction capabilities, which represent microbial signatures known to be harmful to human health (Qin et al., 2012; Triantafyllou et al., 2014) .
The impact of microbial dysbiosis on human health is not limited to peripheral diseases, but may also extend to several brain pathologies (Fang, 2016; Finegold et al., 2012; Hill et al., 2014; Kang et al., 2013; Le Chatelier et al., 2013; Li et al., 2016; Parracho et al., 2005; Williams et al., 2012) . Autism spectrum disorder, which is characterized by deficits in language and social interactions, as well as difficulty interpreting social cues, has been the subject of much recent scrutiny and research, with very little agreement on the root causes of autism to date . However, it has recently been proposed that intestinal microbiota play a pivotal role in the onset of these neurological disorders (Adams et al., 2011; De Angelis et al., 2015; Finegold et al., 2012; Kang et al., 2013; Parracho et al., 2005; Williams et al., 2012; Xiong et al., 2016) . The microbiota of individuals with autism spectrum disorder often include enhanced levels of Bacteroidetes phylum, Sutterella spp., and the toxin-producing bacteria Clostridium histolyticum, with reduced quantities of Firmicutes phylum, Veillonellaceae family, Prevotella spp., and Coprococcus spp. bacteria (Finegold et al., 2012; Kang et al., 2013; Parracho et al., 2005; Williams et al., 2012) . Furthermore, the Clostridium spp.-produced phenylalanine metabolites 3-(3-hydroxyphenyl)-3-hydroxypropionate, 3-hydroxyhippuric acid, and 3-hydroxyphenylacetic acid have been shown to be elevated 15, 27, and 97 fold, respectively, in the urine of children with autism spectrum disorders, when compared to non-autistic children (Xiong et al., 2016) . It has been speculated that these Clostridium spp. metabolites can induce specific autism-like behaviors (Xiong et al., 2016) . Moreover, while both healthy and autistic children have been found to have Clostridium perfringens present in their feces, a clinical study revealed that total C. perfringens was 12-fold greater, and the presence of beta2 toxin gene-positive C. perfringens was 44-fold higher in autistic children, when compared to non-autistic children (Finegold et al., 2017) . The beta2 toxin has been associated with enterotoxemia in a number of mammalian species; however, the potential impact of this toxin on the brain functions has yet to be explored (Dray, 2004; Greco et al., 2005) . It has also been demonstrated that children with autism spectrum disorder display an overall 27% reduction of SCFA levels in their stool, with the exception of propionic and acetic acids (Adams et al., 2011; De Angelis et al., 2015) . This is of particular importance, since propionic acid, which is neurotoxic at high concentrations, has been shown to induce autism spectrum disorder-like symptoms in rodents (El-Ansary et al., 2015) . These finding indicate that high quantities of harmful microbial metabolites may contribute to the pathogenesis of autism spectrum disorder. However, the effects of intestinal microbiota on brain health are not limited to autism spectrum disorder, since microbial dysbiosis has been recently associated with the onset and propagation of several neurodegenerative disorders (Claesson et al., 2012; Dinan and Cryan, 2016) .
Neurodegenerative diseases
A broad variety of brain diseases including ALS, PD and AD are characterized by progressive neuronal loss, cognitive decline or impaired motor function, changes in behavior, and dementia (Spielman and Klegeris, 2014; Tiryaki and Horak, 2014) . Currently, nearly 47 million people suffer from dementia around the world (Prince et al., 2015) . Since many neurodegenerative diseases are age related, the incidence of dementia is expected to rise due to the aging global population (Barnes and Yaffe, 2011) . In fact, the number of neurodegenerative disease cases worldwide is forecasted to escalate to 132 million by the year 2050 (Prince et al., 2015) . It has been calculated that, four to eight percent of all dementias worldwide can be attributed to ALS, a devastating neurodegenerative disorder, characterized by progressive atrophy and weakening of skeletal muscle, dysarthria, dysphagia, dyspnea, cognitive dysfunction, and eventually emotional incontinence (Borasio and Miller, 2001; Tiryaki and Horak, 2014) . Sporadic ALS is known to be associated with a pathogenic mutation in the transactive response DNA-binding protein 43 (TDP-43) gene (Cooper-Knock et al., 2012; Swarup et al., 2011) . This mutation in the TDP-43 gene ultimately leads to aggregation of TDP-43 proteins into toxic cytoplasmic inclusions in neurons and glia (Gendron et al., 2010) . Despite this awareness, the pathology of ALS is poorly understood and relatively understudied compared to many other forms of more prevalent neurodegenerative diseases.
PD affects approximately seven million people worldwide (Calabrese, 2007) . PD is characterized by the deterioration of dopaminergic neurons, primarily in the substantia nigra (SN), and by filamentous deposits of α-synuclein, which aggregate to form insoluble Lewy bodies (Mahlknecht and Poewe, 2013; Marques and Outeiro, 2012; Morris et al., 2011) . These pathological alterations physically manifest as rigidity of muscles, bradykinesia, resting tremors, unsteady balance and posture, changes to speech fluidity, delayed gastric emptying and constipation (Mahlknecht and Poewe, 2013; Santiago and Potashkin, 2013) (Bharucha et al., 2013; Camilleri and Shin, 2013; Fasano et al., 2015; Hardoff et al., 2001; Lin et al., 2014) . Advanced stages of PD, are also associated with a decline in executive function, such as ability to hold attention, plan, make decisions, and multi-task, and have a high comorbidity with limbic system disorders, such as depression and mild cognitive impairment (Chen, 2017; Dirnberger and Jahanshahi, 2013; Dunet et al., 2018) .
AD, which is the most common form of dementia, affects upwards of 40 million people around the world (WHO, 2012). The clinical symptoms of AD include a gradual decline in cognition, memory and functional abilities, as well as alterations in behavior and temperament (McKenzie et al., 2017) . These symptoms have largely been attributed to the manifefstation of two pathological hallmarks: extracellular amyloid beta protein (Aβ) plaques and intracellular neurofibrillary tangles (NFTs); however, other pathological mechanisms could be involved in the onset and progression of the symptoms of AD (Hauw et al., 1990; Pitt et al., 2013; Spielman et al., 2015) .
Inflammation in neurodegenerative diseases
Although each of the aforementioned neurodegenerative diseases presents with unique cellular pathologies and clinical symptoms, there is one feature common to all these diseases: chronic neuroinflammation. The hallmark features of chronic neuroinflammation include overactivation and dysregulation of the immune cells of the brain, the microglia . Under normal homeostatic conditions, microglia remain in a resting state. In this state, microglia take on a ramified shape and continuously extend and retract their cellular processes in search of foreign invaders and pathological stimuli in their nearby environment (Nimmerjahn et al., 2005) . When microglia encounter pathological agents, or detect injury, they become activated and take on an amoeboid morphology. This change in activation status is associated with modifications in the expression pattern of many cell membrane receptors, such as complement receptors, major histocompatibility complex (MHC), CD11a, CD40, and CD80 molecules, all of which have important immune functions (Block et al., 2007; Ousman and Kubes, 2012; Schindler et al., 2014) . Once activated, microglia also alter their secretory profile, by upregulating the release of several chemokines and cytokines, such as interferon (IFN)-γ, IL-6, IL-8, MCP-1, and TNF-α, as well as increase secretion of reactive oxygen species (ROS) and reactive nitrogen species (RNS), all of which are secreted in aims of eliminating the noxious agents (Block et al., 2007; Shemer et al., 2015; Suzumura, 2009) .
Microglial activation and chronic neuroinflammation have been deemed a prominent feature of ALS (Frank-Cannon et al., 2009 ). Studies have shown that levels of the pro-inflammatory mediators IL-8 and MCP-1 are elevated by 22% and 23%, respectively, in the cerebrospinal fluid (CSF) of ALS patients, compared to CSF of control subjects (Kuhle et al., 2009) . ALS patients also exhibit increased activation of immune cells in the spinal cord, as evidenced by an approximate 1.8-fold increase in CD1a expression, a two-fold increase in CD40 expression, a 2.2-fold upregulation in CD14 expression, a 1.4-fold increase in macrophage-colony stimulating factor (M-CSF) expression, and up to sixfold increase in MCP-1 concentration (Henkel et al., 2004) . This study also emphasized that elevated MCP-1 levels in the CSF were predictive of a reduced survival time for ALS patients (Henkel et al., 2004; Kuhle et al., 2009) , thus indicating that the involvement of neuroinflammation may be fundamental in the progression and prognosis of ALS.
Similar observations have been made by clinical studies investigating PD pathogenesis, which demonstrated that α-synuclein can activate microglia in the brains of individuals with PD (Ouchi et al., 2005) . This microglial activation has been shown to coincide with significant increases in markers of neuroinflammation. For example, α-synuclein enhanced microglial expression of MHC II three fold (Harms et al., 2013) and secretion of prostaglandin E2, a potent pro-inflammatory mediator, 2.3 fold (Zhang et al., 2005) . Increases in the expression of the typically pro-inflammatory mediators IL-1α, IL-1β, IL-6, IFN-γ, and TNF-α have been routinely observed in the brains of PD patients (Harms et al., 2013; Sawada et al., 2006) . Moreover, specific polymorphisms in the IL-1β or TNF-α gene increase the risk of developing PD 2.3 fold and 2.5 fold, respectively, while simultaneous polymorphisms the IL-1β and TNF-α genes increased the risk of developing PD 2.9 fold, suggesting that inflammatory genes are fundamental in the development of PD (Wahner et al., 2007) .
In AD, astrocyte and microglia activation has been observed, particularly in the brain regions containing higher concentration of Aβ plaques and NFTs (primarily the frontal cortex and hippocampus) (Mandybur, 1989; Rao et al., 2011; Serrano-Pozo et al., 2011) . It has been observed that, compared to healthy controls, the brains of AD patients exhibit a three-fold increase in IL-1β concentration, a 2.5-fold increase in TNF-α concentrations, a two-fold increase in both cyclooxygenase (COX)-1 and COX-2 expression, as well as a two-fold increase in 12-lipoxygenase (LOX), and a 1.5-fold increase in 15-LOX expression (Rao et al., 2011; Sokolova et al., 2009 ). These findings indicate that AD patients exhibit prominent neuroinflammation in their CNS. In addition, concentrations of C-reactive protein (CRP), an inflammatory marker, are elevated approximately eight fold in the serum of AD patients (Song et al., 2015) . CRP levels have been positively correlated with severity of cognitive decline in elderly individuals, indicating that the chronic neuroinflammation observed in AD may represent a significant contributing factor to the defining symptoms of this disease (Noble et al., 2010) .
Although it is likely the neuroinflammation that occurs in these diseases is initially triggered by the pathological formations in the brain, other aspects of the human immune system may also influence the neuroinflammation observed in these neurodegenerative diseases. Emerging evidence suggests that the composition of, and communication with, the gut microbiota may have a notable impact on modifying the neuroinflammation in these particular neurodegenerative disease states.
Communication between gut microbiota and the brain
The following two distinct mechanisms could be used by gut microbiota for communications with the CNS: 1) the vagus nerve, and 2) transmission of signaling molecules through the circulatory system and across the BBB.
The gut microbiota are able to directly communicate with the CNS by way of the vagus nerve, which originates in the medulla oblongata of the CNS and extends into the periphery supplying the gut, heart, lungs, and other organs of the chest and abdomen with parasympathetic input (Ruffoli et al., 2011; Van Der Zanden et al., 2009) . One of the primary neurotransmitters used by the vagus nerve is acetylcholine (Bonaz et al., 2016; Rang et al., 2007) . Conversely, the thoracic and abdominal organs supply the CNS with visceral and sensory information mediated by chemical input from hormones and regulatory peptides, such as ghrelin, cholecystokinin, glucagon-like peptide 1, and peptide YY (Forsythe et al., 2014; Ruffoli et al., 2011) . Therefore, communication between the gut and the CNS through the vagus nerve represents a bidirectional interaction. This two-way communication is not limited strictly to interaction between human cells of the CNS and human cells of the gut, but may also involve the gut microbiota (de La Serre et al., 2015; Goehler et al., 2005; Nohr et al., 2015) . The somatic sensory ganglia express free fatty acid receptor 3, which is activated by SCFAs, such as propionate. Since SCFAs are mainly produced by intestinal microbiota, the signaling pathways associated with this receptor could be used for communication between the gut microbiota and the CNS (Nohr et al., 2015) . Furthermore, certain SCFA that are known to be produced by microbes, have been proven to have significant impact on brain function. For example, the application of propionate, to neuronal cells, as well as glial cells, leads to temporary intracellular acidification, and in the case of neurons, this intracellular acidification impacts their excitability and signaling potential (Shono et al., 2010; Trudeau et al., 1999) . More specifically, the application of exogenous sodium propionate to cultured rat hippocampal neurons led to rapid intracellular acidification, and subsequently caused transient and variable decreases in excitatory postsynaptic current (Trudeau et al., 1999) . These results were recently confirmed and extended by Bonnet et al. (2018) , who demonstrated that application of 10 mM propionate, or the SCFA DL-ß-hydroxybutyrate, to slices of human temporal gyrus tissue from young males who suffered from epilepsy, led to a reduction of intraneuronal pH, as well as reduction in the over-excitability of human brain tissue (Bonnet et al., 2018) .
It was observed that rodents, orally challenged with Campylobacter jejuni, a microorganism known to cause prominent intestinal infections, experienced increased activity of brain neurons in the vagal sensory ganglia, as well as the nucleus of the solitary tract (Goehler et al., 2005) . Eight hours after the introduction of C. jejuni to the digestive system, a six-fold and 14-fold increase in neuronal activity were observed in the nucleus of the solitary tract and vagal sensory ganglia, respectively, as indicated by an upregulation in c-Fos immunoreactivity (Goehler et al., 2005) . Other studies demonstrated that four weeks of intraperitoneal LPS injections resulted in a seven-fold increase in tolllike receptor (TLR) 4 activation (even though total TLR4 expression was not affected), a 1.4-fold increase in myeloid differentiation primary response 88 (MyD88) expression, a four-fold increase in suppression of cytokine signaling 3 (SOCS3) expression, as well as a two-fold decrease in phosphorylated signal transducer and activator of transcription 3 (STAT3) expression in the nodose ganglion of the vagus nerve, when compared to mice that received saline injections (de La Serre et al., 2015) . Each of these receptors and signaling cascade messengers is well known for their role in recognizing and responding to bacterial antigens and signals. These findings appeared to be specific to the vagus nerve, as similar changes were not detected in the hypothalamus of the same mice. These results, therefore, demonstrate that the gut microbiota could regulate the immune status of the brain by way of the vagus nerve activity (Fig. 1) .
Intestinal microbes can communicate with the brain by secreting signaling molecules that traverse the intestinal epithelium, move through the circulatory system and cross the BBB into the CNS (Crumeyrolle-Arias et al., 2014; Gasperotti et al., 2015; Kido et al., 2000; Moschen et al., 2012) . The presence of transporter molecules, such as the monocarboxylate transporter family proteins along the BBB, which are capable of transporting SCFAs (e.g. butyrate) into the brain, highlights the potential significance of SCFAs in regulation of brain health and function (Kido et al., 2000; Moschen et al., 2012) .
Intestinal microbiota have also been shown to regulate the integrity of the intestinal epithelial barrier (Laval et al., 2015; Rocha et al., 2014) . For example, mice with microbial dysbiosis have reduced expression of occludin by gastrointestinal epithelial cells, as well as increased permeability of the epithelial barrier (Rocha et al., 2014) , while the presence of commensal bacteria, such as Lactobacillus rhamnosus and F. prausnitzii are protective against a leaky gut (Laval et al., 2015) . These two beneficial strains of bacteria increase colonic expression of the tight junction proteins occludin and epithelial (E)-cadherin, which corresponds with a decrease in colon levels of the cytokines IFN-γ, IL-4, and IL-6 (Laval et al., 2015) . Thus, by modulating the integrity of the intestinal mucosal barrier, the microbiota can also have an impact on local intestinal as well as systemic inflammation.
Additionally, gut microbiota can modulate transit of certain molecules across the BBB, by regulating the expression of tight junction proteins at this barrier. More specifically, adult GF mice showed reduced expression of occludin (four-fold decrease) and claudin-5 (fivefold decrease) in the frontal cortex, striatum, and hippocampus, when compared to SPF mice (Braniste et al., 2014) . Colonization of these GF mice with a single gavage of fecal matter from SPF mice, resulted in substantial upregulation in the expression of ZO-1, occludin, and claudin-5 (Braniste et al., 2014) , thus indicating that the introduction of non-pathogenic gut bacteria could positively regulate tight junctions of the BBB.
In addition to regulating the integrity of intestinal barrier and BBB, several gut microbiota metabolites have been shown to traverse both of these barriers, providing evidence for a means of indirect communication between the intestinal microbiota and the cells of the CNS (Gasperotti et al., 2015) . Gallic acid, a microbial-derived metabolite of dietary polyphenols, preferentially accumulates in the brains of human hosts since its concentrations in the brain exceed the levels of gallic acid in the blood and kidneys by greater than six fold and three fold, respectively (Gasperotti et al., 2015) . This is of particular significance, since gallic acid has been shown to have many beneficial effects in the brain, including improving hippocampal long-term potentiation and cognition (Sarkaki et al., 2014) . Additionally, trimethylamine-N-oxide (TMAO), a microbial metabolite of dietary choline and carnitine, has also been discovered to be present in the CNS of humans (Del Rio et al., 2017) , further indicating that microbial metabolites migrate to the human brain.
It has become increasingly documented that the gut microbiota play an important role in the development and moderation of endocrine signaling along the hypothalamic-pituitary-adrenal (HPA) axis, which sends and receives signals by transporting hormones across the BBB and through the circulatory system (Sudo, 2014) . For example, GF mice had higher expression of brain corticotropin-releasing hormone and lower expression of glucocorticoid receptors, compared to SPF mice (Crumeyrolle-Arias et al., 2014) . This increase in the brain stress-response in the GF mice correlated with up to 2.8-fold greater serum corticosterone concentrations, as well as enhanced anxiety-like behavior, following the introduction of stress, when compared to SPF mice (Crumeyrolle-Arias et al., 2014). These results indicate that a certain level of non-pathogenic intestinal bacterial may be important for appropriate/normal human stress response. Other studies have confirmed that gut microbiota impact HPA responses by demonstrating that oral administration of Lactobacillus farminis supresses stress-induced endothelial hyperpermeability and reduces the HPA axis-mediated stress response (Ait-Belgnaoui et al., 2012). Mice inoculated with L. farminis showed diminished translocation of fluorescein isothiocyanate (FITC)-dextran across the colonic strip, as well as reduced LPS concentrations in the portal blood (Ait-Belgnaoui et al., 2012) . This reduction in gut permeability coincided with an approximate 2.5-fold decrease in the expression of corticotropin-releasing hormone and IL-6 alike, a two-fold decline in IL-1β expression, and a three-fold reduction in TNF-α expression in the hypothalamus (Ait-Belgnaoui et al., 2012) . Thus, it is evident that the gut microbiota can influence neuroinflammation through altered HPA responses and signaling.
Gut microbiota and neurodegeneration
Recent investigations have highlighted the importance of gut microbiota in the development, function and healthy aging of the brain (Dinan and Cryan, 2016) . Human studies have emphasized that diverse and stable gut microbiota enhance markers of overall health in the elderly, including lower levels of systemic inflammation, as well as lead to healthy body weight, decreased frailty, and ultimately, increased host longevity (Claesson et al., 2012; Dinan and Cryan, 2016) . Therefore, in addition to helping extend an individual's total lifespan, maintaining a healthy gut microbiota can also help extend the number of healthy years lived (health span) (Caini et al., 2016; Chen et al., 2016; Dobbs et al., 2012; Goldman et al., 2014; Jost, 2010; Keshavarzian et al., 2015; Kondrashova et al., 2005; Okada et al., 2010; Scheperjans et al., 2015) .
Animal studies have provided several helpful clues showing that diverse and healthy gut microbiome may promote brain health by preventing the development of neurodegenerative diseases and disorders. For example, peripheral administration of Lactobacillus spp. has also shown to have an anti-inflammatory and antioxidant effect in the brains of rats with cerebral ischemia (Wanchao et al., 2018; Xu et al., 2018) . Rats with cerebral ischemia reperfusion injury that were treated intravenously with inactivated Lactobacillus experienced a decrease in brain cell apoptosis, as well as an increase in the antioxidant superoxide dismutase (SOD) (Wanchao et al., 2018) .
It was shown that administration of several broad-spectrum antibiotics including, ampicillin/sulbactam, vancomycin, or imipenem/cilastatin/metronidazole, severely depleted the intestinal microbiota in mice, and also reduced hippocampal neurogenesis in these rodents by approximately two fold (Mohle et al., 2016) . This antibiotic-induced decline in neurogenesis was restored in mice who received the probiotic cocktail VSL#3, which contains Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillis acidophilus, Lactobacillis casei, Lactobacillis plantarum, Lactobacillis delbrueckii subsp. Bulgaricus, and Streptococcus salivarius subsp. Thermophiles. Administration of the VSL#3 probiotic had beneficial gastrointestinal health effects, such as reduced intestinal permeability following intestinal injury, as well as reduced symptoms of 2,4,6-trinitrobenzenesulfonic acid-induced colitis in rats (Chang et al., 2013; Uronis et al., 2011) . These studies, therefore, illustrate that intestinal microbiota can have a significant influence on brain neurogenesis, which is crucial for preventing the age-related cognitive and memory impairments (Mohle et al., 2016) . Other studies highlighted that the long-term administration of VSL#3 changed the composition of the intestinal microbiota of aged rats, most notably by increasing the proportion of the phylum Actinobacteria and the genus Bacteroides (Distrutti et al., 2014) . This was accompanied by enhanced hippocampal expression of a number of genes involved in synaptic plasticity, including BDNF, synapsin and syntaxin, which also correlated with a reversal in the age-related decline of long-term potentiation, a process that is critical to memory formation and retention (Distrutti et al., 2014) . Normal aging is associated with a small decline in the regeneration of neurons, which correlates with minor reductions in cognitive function and memory (Craik, 1990) ; however, when impairment of neuronal regeneration becomes excessive and is accompanied by pathological formations, neurodegeneration can occur. 
Gut microbiota and amyotrophic lateral sclerosis
Although ALS is largely characterized by neurodegeneration and muscular weakness, research shows that this multi-system disorder is also associated with gastrointestinal symptoms, including a delay in gastric emptying, as well as reduced colonic transit times (Fang, 2016; Toepfer et al., 1999) . A recent clinical study examining stool from a small group of patients found that gastrointestinal symptoms preceded neurological symptoms in ALS patients, and also demonstrated that all ALS patients display a decreased diversity in their intestinal microbiome, compared to healthy controls (Rowin et al., 2017) .
The gastrointestinal pathologies observed in ALS patients may be related to the increased intestinal permeability detected in patients with this disease (Fang, 2016; Wu et al., 2015) . The increased gut permeability consistently observed in ALS patients has been shown to result in an approximately two-fold increase in circulating levels of LPS when compared to healthy control subjects, which is concurrent with an upregulated activation of monocytes (Zhang et al., 2009) .
In ALS patients, the blood-spinal cord barrier (BSCB) and the BBB exhibit reduced membrane integrity (Bataveljic et al., 2014; GarbuzovaDavis et al., 2012; Henkel et al., 2009 ). The BSCB of ALS patients has an approximately 25% reduction in the expression of ZO-1, compared to healthy controls (Henkel et al., 2009 ). Other studies have confirmed and extended this finding by demonstrating an up to 2.7-fold reduction in brain ZO-1 expression, a two-fold reduction in occludin expression, a three-fold decline in claudin-5 expression, a 2.5-fold decline in junction adhesion molecule (JAM)-1 expression, and a 1.8-fold decline in vascular endothelial (VE)-cadherin expression along the BBB and BSCB in the brains of ALS patients (Garbuzova-Davis et al., 2012) . These major changes in the expression of tight junction proteins in ALS patients corresponded with an approximate 3.5-fold increase in BBB permeability. Enhanced BBB leakage also correlated with increased markers of immune cell infiltration, as well as exacerbated CNS inflammation (Bataveljic et al., 2014) . For example, it was shown that impaired integrity of the BBB in ALS patients led to increased brain and spinal cord infiltration of macrophages and mast cells, as well as upregulated COX-2 levels (Graves et al., 2004) .
Mice models of ALS also exhibit altered gut microbial colonization characterized by reduced relative abundance of fecal E. coli, Firmicutes peptostreptococcus, and Butyrivibro fibrisolvens, (approximately 50% decreased representation of each) compared to wild-type mice . These abnormalities in gut microbiota correlate with a 50% reduction in colonic expression of ZO-1 and a 25% reduction in E cadherin compared to wild-type mice, which leads to a near four-fold increase in gut permeability. ALS mice also display an increase in overall systemic inflammation, as indicated by a nearly 1.5-fold upregulation in intestinal IL-17 and a 1.6-fold increase in serum IL-17 . Moreover, the G29A mouse models of ALS undergo a change in intestinal microbiota prior to the onset of ALS-like symptoms Zhang et al., 2017) .
Combined, these data indicate that ALS pathology could be, at least partially, driven by alterations of the intestinal microbiota, which facilitates systemic inflammation, as well as deficiencies in the intestinal and CNS barriers. Specific factors derived from adversely altered intestinal microbiota may contribute to the pathogenesis of ALS in a neuroimmune-specific manner (Fig. 2) .
Gut microbiota and Parkinson's disease
Although there are several defining cellular and molecular characteristics of PD, it has been suggested by some experts that PD may arise from intestinal pathologies, and that the intestinal microbiota play an essential role in the initiation and propagation of PD (Holmqvist et al., 2014) . Intestinal microbial overgrowth, which is defined as an excessive increase in coliform bacteria, has been found to be common in PD patients (Gabrielli et al., 2011; Niu et al., 2016; Sachdev and Pimentel, 2013) . The nearly two-fold increase in urinary concentrations of indican (an indicator of microbial dysbiosis) in the urine of PD patients suggests that intestinal microbiota may play a critical role in the pathogenesis of PD (Cassani et al., 2015) .
The fecal microbial community of PD patients can differ significantly from individuals who do not have PD (Keshavarzian et al., 2015) . It was discovered that the typically beneficial and anti-inflammatory butyrate-producing bacteria belonging to the genera Blautia, Coprococcus, and Roseburia were reduced in the feces of PD subjects, when compared to feces from healthy controls, while the typically pro-inflammatory gram-negative bacteria from the Ralstonia genus were much more abundant in the intestinal mucosa of PD patients when compared to healthy controls (Keshavarzian et al., 2015) . Furthermore, elevated abundance of Eubacterium eligens, Eubacterium rectale, and Eubacterium hallii were positively correlated with higher Unified Parkinson's Disease Rating Scale (UPDRS) scores in PD patients indicating a worsening disease state (Bedarf et al., 2017) . Others have verified that a reduced abundance of Prevotella spp. and an increased abundance of Enterobacteriaceae family bacteria are common in PD patients (Scheperjans et al., 2015) . Prevotella are generally regarded as beneficial bacteria, as they are known to metabolize many plant polysaccharides and vitamins into beneficial bioactive compounds, and have been positively associated with the production of neuroactive SCFAs, such as GABA (Flint and Bayer, 2008; Patterson et al., 2014; Sanchez et al., 2009; Scheperjans et al., 2015; Wu et al., 2011) . Reduced levels of Prevotella spp. are also associated with diminished mucin production (Bergstrom and Xia, 2013) . Mucin proteins are high Fig. 2 . The role of gut microbiota in the pathogenesis of amyotrophic lateral sclerosis. ALS, amyotrophic lateral sclerosis; BBB, blood brain barrier; BSCB, blood spinal cord barrier; COX, cyclooxygenase; E, epithelial; IL, interleukin; JAM, junction adhesion molecule; LPS, lipopolysaccharide; VE, vascular endothelial; ZO, zonula occludens. molecular weight O-linked glycoproteins, which line mucosal surfaces and aid in maintaining the integrity of the epithelial barrier. A reduction in mucin synthesis is associated with increased intestinal permeability, a clinical feature associated with both microbial dysbiosis and PD (Bergstrom and Xia, 2013; Forsyth et al., 2011; Rocha et al., 2014) . However, not all experts agree that the association between the microbial dysbiosis and PD is related to the compromised integrity of the intestinal mucosa (Hasegawa et al., 2015) .
Disruption of the BBB is prevalent in individuals with PD, which may contribute to the notably selective increased death of dopaminergic neurons in the SN (Fang, 2016; Lee et al., 2015) . It is possible that the combination of reduced integrity of the intestinal barrier and the BBB allows for increased indirect communication between gut microbiota and cells of the CNS. Peripheral injections of LPS have been used to model PD in mice, since they produce a PD-like phenotype, which includes SN-selective neurotoxicity (Castano et al., 1998; Herrera et al., 2000; Hoban et al., 2013; Qin et al., 2013; Tomas-Camardiel et al., 2004) . Minocycline, a broad-spectrum antibiotic known to alter the composition of intestinal microbiota, has significant protective impact on LPS-induced PD symptoms in mice (Tomas-Camardiel et al., 2004; Zaura et al., 2015) . Intraperitoneal injections of minocycline in PD mice, resulted in marked amelioration of SN inflammation, as indicated by an almost two-fold reduction in TNF-α expression, a 1.3-fold reduction in IL-1α expression, a near two-fold decline in microglia activation, as well as a 1.6-fold reduction in astrocyte death (TomasCamardiel et al., 2004) . The LPS-injected mice that received minocycline treatment also experienced a 1.8-fold increase in the number of surviving dopaminergic neurons in the SN, compared to control LPS only-injected mice (Tomas-Camardiel et al., 2004) . Thus, antibiotics, which are known to alter gut microbial diversity, can impact inflammation-induced PD, highlighting a potential neuroimmune-specific mechanism of microbial-CNS communication in PD patients. These findings were confirmed and extended by observations that SPF mice who orally received SCFAs from either wild-type mice, or PD-model mice differed greatly in their markers of microglia activation (Sampson et al., 2016) . SPF mice that received SCFAs from the PD-model mice demonstrated a 10-fold increase in microglial CD11b, when compared to SPF mice that received SCFAs from wild-type mice (Sampson et al., 2016) . This dramatic difference in microglia activation was accompanied by marked disparity in motor abilities between these two groups of mice. The SPF mice that received SCFAs from wild-type mice outperformed their counterparts two-three fold on a variety of murine motor skills tests. These results establish that microbial metabolites from healthy mice can be beneficial to murine brain health, while microbial metabolites from PD mice can potentially enhance neuroinflammation.
The incidence of PD has been shown to be higher in Crohn's disease, ulcerative colitis patients and IBD, compared to individuals who do not suffer from these conditions (Nalls et al., 2014; Villumsen et al., 2018) . Although the root cause of ulcerative colitis is currently unknown, many experts believe this disease has bacterial origins (Campieri and Gionchetti, 2001) . Murine studies have revealed that ulcerative colitis, which damages the intestinal barrier, leads to increases in serum levels of CRP (approximately 1.4 fold), IL-1β (approximately 1.8 fold), IL-6 (approximately 1.8 fold), and TNF-α (approximately two fold) (Villaran et al., 2010) . Mice with ulcerative colitis, which received injections of LPS in the SN, experienced an approximately two-fold increase in activation of microglia around the injection sites, as indicated by upregulation of the microglia activation marker CD74, a two-fold increase in TNF-α expression, as well as a two-fold increase in inducible nitric oxide synthase (iNOS) expression in the SN, compared to their ulcerative colitis-free counterparts (Villaran et al., 2010) . Thus, intestinal microbiota associated with IBD can potentially have a significant impact on CNS inflammation following peripheral inflammatory injury.
Human studies confirm and extend these rodent-model findings. A recently published 40-year-long Danish study discovered that individuals with IBD were at a 22% greater risk of developing PD, compared to non-IBD individuals (Villumsen et al., 2018) . Additionally, two gastrointestinal irregularities have been consistently observed in individuals with PD at a rate much higher than in age-and sex-matched healthy controls: delayed gastric emptying and constipation (Bharucha et al., 2013; Camilleri and Shin, 2013; Fasano et al., 2015; Hardoff et al., 2001; Lin et al., 2014) . A longitudinal study performed in Taiwan demonstrated that constipation increased the risk of a person developing PD by approximately 3-11 fold (depending on severity of the symptoms), thus confirming constipation as one of the non-motor symptoms of PD (Lin et al., 2014) . Intestinal bacteria can have a dramatic effect on intestinal function, including gastric emptying and constipation (Quigley, 2011; Zhao and Yu, 2016) . Mertsalmi et al. (2017) proposed that constipation in PD patients with IBS-like symptoms may be due to the lower abundance of Prevotella bacteria in these patients compared to PD patients who did not experience severe gastrointestinal symptoms (Mertsalmi et al., 2017) . The above studies demonstrate that there are associated changes in microbiota compositions in individuals with PD, but most cases cannot identify whether this relationship is causative. Current studies cannot rule out that constipation may be caused by PD and subsequently leads to changes in gut microbiota.
Human studies demonstrate that Helicobacter pylori infections are much more common in PD patients when compared to the general population (14% versus four %) (Dobbs et al., 2000 (Dobbs et al., , 2010 . A doubleblind clinical trial was initiated to assess the contribution of H. pylori to PD pathology. It was discovered that eradication of H. pylori infection in PD patients considerably improved disease symptoms, including increased stride length and reduced rigidity, independent of the use of PD medications (Dobbs et al., 2010) . A follow-up study by the same group confirmed that H. pylori infection, as well as bacterial overgrowth in PD patients, was associated with elevated counts of natural-killer cells (CD16+/CD56+) and a greater number of T-helper cells (CD4 + ), which increased the severity of PD symptoms, including shorter stridelength, decreased free-walking speed, and increased rigidity (Dobbs et al., 2012) . Additionally, several single-nucleotide polymorphisms in the genes of peptidoglycan recognition protein (PGLYRP) 2, PGLYRP-3, and PGLYRP-4, which help regulate immune response to both commensal and pathogenic bacteria, have been associated with PD (Goldman et al., 2014) . Specific gastrointestinal issues, such as constipation, which are well understood to be influenced by intestinal microbiota, have been noted to precede the motor symptoms of PD (Jost, 2010) .
Further evidence to support PD as a gut microbiota-related disease comes from studies showing that the pathological hallmarks of PD, α-synuclein protein aggregates, are routinely found within the neurons of the peripheral nervous system, including enteric neurons in the gut (Cersosimo et al., 2013; Natale et al., 2011) . Using adult wild-type Sprague Dawley rats, Holmqvist et al. (2014) determined that α-synuclein protein lysates, which were taken from human PD patients and injected into intestinal wall of a rat, traveled to the dorsal motor nucleus by way of the vagus nerve in a time-dependent manner (Holmqvist et al., 2014) . Twelve hours after injection, α-synuclein was detected in the intestinal wall, but could barely be detected in the vagus nerve. However, two days after injection, α-synuclein became detectable in the vagus nerve, and six days post-injection, α-synuclein could be detected in the brainstem of these rats, clearly indicating that α-synuclein was transported from the peripheral nervous system to the CNS. Since intestinal microbiota can communicate with the CNS by way of the vagus nerve, and have been shown to impact intestinal absorption, it is possible that gut microbes have a role in transport of α-synuclein from the gut to the CNS (de La Serre et al., 2015; Goehler et al., 2005; Nohr et al., 2015; Weaver, 2015) . Thus, evidence is accumulating that PD may initiate in the gut, or at very least, that gut microbiota can have an impact on the pathogenesis of PD, particularly through neuroinflammatory mechanisms (Fig. 3) . L.J. Spielman et al. Neurochemistry International 120 (2018) 149-163 4.3. Gut microbiota and Alzheimer's disease
In addition to impacting the pathology of ALS and PD, gut microbiota may also have a regulatory role in the pathogenesis of AD (Szablewski, 2018) . Studies have indicated that poor diet, in particular excessive high-fat diets (high saturated fats and high cholesterol), poses an increased risk for developing AD (Pasinetti et al., 2007; Theriault et al., 2016; Thirumangalakudi et al., 2008) . Some high-fat diets, such as those rich in corn oil, increase intestinal permeability in rodents (Johnson et al., 2015; Kawano et al., 2016; Wang et al., 2015b; Zhang et al., 2009 ); however, not all high-fat diets have demonstrated negative impact on intestinal permeability (Lee et al., 2016) . Some reports have revealed that elevated amounts of consumed n-3 polyunsaturated fatty acids are not associated with the development of AD (Bayer-Carter et al., 2011; Gu and Scarmeas, 2011) . The possible increased risk of AD associated with varying diets, including certain high saturated-fat diets, may be due to detrimental alterations in the composition of gut microbiota. For example, it has been shown that mice fed diets high in unsaturated fatty acids exhibit a microbial signature low in Lactobacillus spp. Bacteroides spp., and Prevotella spp., but higher in Bifidobacterium spp., compared to control diet-fed mice, which correlated with an approximately eight-fold increase in intestinal permeability (Cani et al., 2008) . This increase in gut permeability was likely due to the associated reduction in ZO-1 (1.6 fold) and occludin (1.2 fold) expression in the gut. The increase in intestinal permeability coincided with 2.5-fold higher plasma LPS concentration, as well as a 1.4-fold increase in serum IL-1, and a 1.7-fold increase in serum TNF-α (Cani et al., 2008) . Cani et al. (2008) further demonstrated that oral administration of the antibiotics ampicillin/neomycin to the high-fat diet-fed mice, modified their gut microbiota composition to represent less Bifidobacterium spp. and more Lactobacillus spp., Bacteroides spp., and Prevotella spp., thus, resulting in a microbial signature that more closely resembled the control group. This antibiotic-induced normalization in gut microbiota corresponded to an increase in gut ZO-1 and occludin expression, thus, reversing the intestinal permeability associated with the high-fat diet (Cani et al., 2008) . These findings highlight that diet can have a significant impact on microbial composition, and can subsequently affect intestinal integrity and alter the risk for developing AD. These sometimes seemingly conflicting results related to dietary fat and risk for developing AD, may be due in part to the inconsistency or lack of specificity in high-fat diet types utilized by various murine studies.
Increased intestinal permeability can lead to elevated levels of serum LPS in AD patients by approximately three fold compared to healthy controls, which is coupled with considerable activation of monocytes (Zhang et al., 2009) . AD patients also have reduced integrity of their BBB, which can lead to adverse activation of microglia and ultimately to the induction of a chronic neuroinflammatory state (Wada, 1998; Zlokovic, 2005) . The combined increase in both gut and BBB permeability may permit for increased adverse signaling between the gut microbes and cells of the CNS.
Although it is the excess accumulation of Aβ plaques and NFTs that is said to trigger neuroinflammation in AD, the systemic inflammation, which is consistently observed in AD patients, has been shown to exacerbate this effect (Calsolaro and Edison, 2016; Rao et al., 2011; Sokolova et al., 2009) . Therefore, the microbial dysbiosis that causes increased epithelial and endothelial barrier permeability and systemic inflammation could act synergistically to accelerated AD pathology in a neuroimmune-specific manner. This notion is supported by observations that individuals with IBS, a condition characterized by microbial dysbiosis, are at a 1.8-fold greater risk for developing AD , while ulcerative colitis patients have a 2.4-fold higher rate of mortality due to AD, compared to the general population (Caini et al., 2016) .
Gut microbiota also have a direct impact on the biomarkers of AD. Xu and Wang (2016) discovered that over 50 microbial metabolites were positively associated with accelerated cognitive decline, earlier L.J. Spielman et al. Neurochemistry International 120 (2018) 149-163 age of AD onset and biomarkers of disease progression in AD patients (Xu and Wang, 2016) . Among these identified bacterial metabolites was TMAO, a well-known intestinal microbial metabolite of dietary animal fats. TMAO was identified as consistently being associated with AD, which lends further support to the epidemiological findings that highfat "western diets" are positively correlated with increased risk of AD. Furthermore, several bacterial species, including Bacillus subtilis, E. coli, Mycobacterium tuberculosis, Salmonella enterica, Salmonella typhimurium, and Staphylococcus aureus, are capable of producing amyloid fibers (Larsen et al., 2008; Oli et al., 2012; Pistollato et al., 2016) . Incubation of the E. coli endotoxin with Aβ exacerbated Aβ fibril formation, thereby demonstrating that LPS can enhance the amyloid burden observed in AD brains (Asti and Gioglio, 2014) . It has also been demonstrated that Aβ is capable of crossing the intestinal barrier, as well as the BBB Takechi et al., 2009; Zlokovic, 1996) . Thus, it is possible that the amyloid fibers produced by various bacterial species are capable of priming the peripheral immune system, and subsequently enhancing the neuroinflammatory responses to Aβ in the brain (Friedland, 2015) . It is also conceivable that peripherally-produced microbial amyloid proteins could be deposited in the CNS and promote AD pathogenesis (Holmqvist et al., 2014) . Aβ monomer clearance from the CNS appears to be dependent on the triggering receptor expressed on myeloid cells-2 (TREM2) (Rivest, 2015; Zhao and Lukiw, 2015) , a receptor that is expressed by microglial cells. This receptor has a number of important functions in the CNS, including Aβ sensing and induction of phagocytosis, cytokine production, as well as ROS and RNS production by microglia (Zhao and Lukiw, 2015) . The expression of functional TREM2 is downregulated in AD brains, and it has recently been discovered that inflammatory toxins, such as LPS, can drastically diminish TREM2 expression and reduce the TREM2-mediated phagocytosis of cellular debris (by up to 25 fold) (Gawish et al., 2015; Melchior et al., 2010; . Thus, in addition to potentially contributing to Aβ fibril production, intestinal microbiota may play a role in trapping Aβ in AD brains, which, in turn, could further aggravate AD pathology.
Gut microbiota are also able to reduce the Aβ load in AD patients through indirect diet-mediated mechanisms. Male Sprague-Dawley rats, that were fed grape seed polyphenol extracts, experienced a substantial accumulation of the microbial grape seed polyphenol extracts metabolites 3-hydroxybenzoic acid and 3-(3′-hydroxyphenyl) propionic acid in the brain (2.5-fold and 4.5-fold increase, respectively) (Wang et al., 2015a) . These particular polyphenol metabolites have been shown to interfere with the oligomerization of Aβ, thereby, potentially reducing one of the markers of AD pathology (Wang et al., 2015a) . Thus, it is possible that while certain bacteria may have the ability to promote AD pathogenesis, other bacteria may help reduce AD pathology. This notion is supported by other findings, such as the discovery that Lactobacillus spp. and Bacillus spp. have the ability to produce acetylcholine, a neurotransmitter reduced in the brains of AD patients (Kawashima et al., 2007; Wall et al., 2014) . It can be hypothesized that healthy gut microbiota aid in cholinergic signaling by way of the vagus nerve (Partosoedarso and Blackshaw, 2000) .
Investigations utilizing GF mice, as well as mice treated with probiotics or antibiotics, indicate that, in addition to impacting the molecular hallmarks of AD, bacteria have an important role in regulating learning, memory, and cognition . Experiments utilizing specific diets to induce changes in gut microbiota composition revealed that mice fed "western diets", which are high in saturated fats, had increased levels of Firmicutes phylum and Rumunococcus genus, and lower representation of Bacteroidetes phylum when compared to the control mice fed normal chow (Pyndt Jorgensen et al., 2014) . These changes in gut microbiota in the high-fat diet-fed group corresponded with a substantial decline in memory capabilities (Pyndt Jorgensen et al., 2014) .
Antibiotic-induced microbial dysbiosis has been shown to reduce colonic levels of the microbial-derived products including acetate, butyrate, propionate, TMAO, adenine, and uracil. The decline in microbial metabolites in mice was associated with reduced CNS levels of BDNF (up to 25% decrease), as well as a reduction in memory (approximately three-fold decline) (Frohlich et al., 2016) . Experiments involving GF mice inoculated with feces from SPF mice confirmed and extended these results by demonstrating that the brain concentration of select molecules can be highly influenced by intestinal microbiota (Matsumoto et al., 2013) . For example, it was determined that TMAO, an alkylamino acid which has been shown to restore the ability of mutant tau to promote microtubule assembly, was at 4.4-fold higher concentration in the brains of GF mice, which had been inoculated with feces from SPF animals, compared to GF mice that had not been inoculated. Therefore, certain intestinal microbiota may have a significant impact on regulating NFT formation in AD (Matsumoto et al., 2013; Smith et al., 2000) . Additionally, disruptions in intestinal microbiota at an early age have an impact on inflammation and amyloid pathology in aged double-transgenic mouse model of AD (APP SWE / PS1 ΔE9 ) (Minter et al., 2017) . More specifically, APP SWE /PS1 ΔE9 mice, which received post-natal antibiotics, had a much higher representation of Lachnospiraceae, and a lower representation of Bacteriodes, compared to APP SWE /PS1 ΔE9 mice that did not receive post-natal antibiotics (Minter et al., 2017) . The APP SWE /PS1 ΔE9 mice receiving post-natal antibiotics also exhibited two-fold lower plaque burden, and a corresponding 2.5-fold and 1.7-fold reduction in plaque-associated astrocytes and microglia, respectively, compared to APP SWE /PS1 ΔE9 mice that did not receive post-natal antibiotics (Minter et al., 2017) . These data further indicate that intestinal microbiota may be important in regulating the progression of AD pathologies.
A preliminary clinical trial established that AD patients with H. pylori infections exhibited enhanced levels of phosphorylated tau (1.4 fold) and total tau (1.6 fold), as well as increased levels of IL-8 (1.4 fold) and TNF-α (1.3 fold) in the CSF, compared to H. pylori-negative AD patients (Roubaud-Baudron et al., 2012) . These changes in CNS inflammation and AD markers in H. pylori-infected individuals corresponded with an 18% greater decline in standard measures of cognitive abilities compared to H. pylori-free AD patients. Taken together, these data establish that gut microbiota are capable of regulating cellular and molecular features of AD, as well as the clinical symptoms of this disease, and that intestinal microbiota may assert their influence on brain pathologies through various indirect neuroinflammatory mechanisms (Fig. 4) .
Conclusion
Intestinal microbiota can modulate a variety of host brain activities and behaviors by way of the microbiota-gut-brain axis. Normal intestinal microbiota impact host health through a variety of different mechanisms, including the digestion of complex carbohydrates, alteration of the intestinal absorption of nutrients, the secretion of microbial metabolites, the production of vitamins and neurotransmitters, as well as the modification of the intestinal epithelial barrier and the BBB permeability (Barrett et al., 2012; Biesalski, 2016; Braniste et al., 2014; Hu et al., 2016; Morrison and Preston, 2016; Stevens and Hume, 1998; Tojo et al., 2014; Valdes et al., 2015) . A diverse and rich intestinal microbial population has been shown to have a positive association with host brain health, while microbial dysbiosis and intestinal infections have a proven negative association with human brain health (Fang, 2016; Hill et al., 2014; Le Chatelier et al., 2013; Li et al., 2016) . Studies using GF mice and SPF animals exposed to antibiotics and probiotics, as well as human clinical trials have demonstrated the significant impact that intestinal microbes may have on the pathology and symptoms of ALS, PD, and AD (Fang, 2016; Hu et al., 2016) .
There is now significant evidence that intestinal microbiota have the ability to modulate the pathologies of these diseases through neuroinflammatory mechanisms. Future studies could focus on strategies for modulating intestinal microbiota populations in individuals at risk for developing neurodegenerative brain diseases. Such studies could lead to therapeutic approaches enriching and stabilizing healthy intestinal microbiota, thereby alleviating neuroinflammation, and possibly delaying the onset or reducing the prevalence of human neurodegenerative diseases.
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